CY1124034T1 - ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-p - Google Patents
ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-pInfo
- Publication number
- CY1124034T1 CY1124034T1 CY20211100361T CY211100361T CY1124034T1 CY 1124034 T1 CY1124034 T1 CY 1124034T1 CY 20211100361 T CY20211100361 T CY 20211100361T CY 211100361 T CY211100361 T CY 211100361T CY 1124034 T1 CY1124034 T1 CY 1124034T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alzheimer
- antibody
- delaying
- onset
- disease
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000000178 monomer Substances 0.000 abstract 3
- 230000009260 cross reactivity Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124034T1 true CY1124034T1 (el) | 2022-05-27 |
Family
ID=42832352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100361T CY1124034T1 (el) | 2009-06-29 | 2021-04-27 | ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-p |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (enExample) |
| EP (2) | EP3892633A1 (enExample) |
| JP (3) | JP2012532094A (enExample) |
| AU (1) | AU2010267640B2 (enExample) |
| CA (1) | CA2765602C (enExample) |
| CY (1) | CY1124034T1 (enExample) |
| DK (1) | DK2448968T3 (enExample) |
| ES (1) | ES2864049T3 (enExample) |
| HR (1) | HRP20210611T1 (enExample) |
| HU (1) | HUE053949T2 (enExample) |
| LT (1) | LT2448968T (enExample) |
| PL (1) | PL2448968T3 (enExample) |
| PT (1) | PT2448968T (enExample) |
| SI (1) | SI2448968T1 (enExample) |
| SM (1) | SMT202100237T1 (enExample) |
| WO (1) | WO2011001366A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| CN101421303B (zh) | 2006-03-23 | 2013-06-12 | 生命北极神经科学公司 | 改进的初原纤维选择性抗体及其用途 |
| HRP20180230T8 (hr) | 2010-02-26 | 2021-04-30 | Bioarctic Neuroscience Ab | Protutijela koja se vežu na protofibrile i njihova upotreba u terapijskim i dijagnostičkim postupcima kod parkinsonove bolesti, demencije s lewyjevim tijelima i drugih alfa-sinukleinopatija |
| SG192805A1 (en) | 2011-03-16 | 2013-09-30 | Probiodrug Ag | Diagnostic antibody assay |
| MY184890A (en) | 2014-07-10 | 2021-04-29 | Bioarctic Neuroscience Ab | Improved a? protofibril binding antibodies |
| US11327080B2 (en) | 2015-07-21 | 2022-05-10 | BioArctic Neruoscience AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| EP3484918A1 (en) | 2016-07-14 | 2019-05-22 | BioArctic Neuroscience AB | Brain delivery protein |
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| JP7541505B2 (ja) | 2018-07-24 | 2024-08-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病の治療及び予防方法 |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US20220251518A1 (en) * | 2019-07-08 | 2022-08-11 | Terumo Kabushik Kaisha | Hybridoma, method for making the same, monoclonal antibody, and method for making the same |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| FI4172199T3 (fi) | 2020-06-26 | 2025-08-12 | Bioarctic Ab | Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet |
| EP4367516A1 (en) | 2021-07-09 | 2024-05-15 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| EP4395821A1 (en) | 2021-08-30 | 2024-07-10 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| US20250377367A1 (en) | 2022-02-02 | 2025-12-11 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| KR20250134612A (ko) | 2022-12-22 | 2025-09-11 | 바이오악틱 에이비 | Abetape3에 결합하는 항체 |
| US20250388664A1 (en) | 2024-06-20 | 2025-12-25 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| WO2001010900A2 (en) * | 1999-08-04 | 2001-02-15 | University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
| JP5362164B2 (ja) | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病の予防及び治療 |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1911765A3 (en) * | 2002-07-24 | 2008-04-23 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation |
| EP2067789A1 (en) * | 2004-04-13 | 2009-06-10 | F. Hoffmann-La Roche Ag | Anti-P selectin antibodies |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EA016357B1 (ru) * | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Антитела, направленные против бета-амилоидного пептида, и способы их применения |
| CN101421303B (zh) * | 2006-03-23 | 2013-06-12 | 生命北极神经科学公司 | 改进的初原纤维选择性抗体及其用途 |
| MY158903A (en) * | 2007-11-16 | 2016-11-30 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
| ES2709048T3 (es) * | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
-
2010
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019218362A (ja) | 2019-12-26 |
| CA2765602A1 (en) | 2011-01-06 |
| US20120100129A1 (en) | 2012-04-26 |
| EP2448968A1 (en) | 2012-05-09 |
| CA2765602C (en) | 2021-05-25 |
| SI2448968T1 (sl) | 2021-07-30 |
| JP2012532094A (ja) | 2012-12-13 |
| EP3892633A1 (en) | 2021-10-13 |
| HRP20210611T1 (hr) | 2021-05-28 |
| PT2448968T (pt) | 2021-04-30 |
| AU2010267640B2 (en) | 2015-03-05 |
| JP6884025B2 (ja) | 2021-06-09 |
| ES2864049T3 (es) | 2021-10-13 |
| PL2448968T3 (pl) | 2021-09-13 |
| HUE053949T2 (hu) | 2021-08-30 |
| SMT202100237T1 (it) | 2021-05-07 |
| EP2448968B1 (en) | 2021-01-27 |
| US20230295283A1 (en) | 2023-09-21 |
| JP2017197531A (ja) | 2017-11-02 |
| LT2448968T (lt) | 2021-05-10 |
| DK2448968T3 (da) | 2021-04-12 |
| AU2010267640A1 (en) | 2012-01-19 |
| WO2011001366A1 (en) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124034T1 (el) | ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-p | |
| CY1121209T1 (el) | Αντισωματα και εμβολια προς χρηση σε θεραπευτικες και διαγνωστικες μεθοδους για σχετιζομενες με αλφα-συνουκλεϊνη διαταραχες | |
| CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
| CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
| CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CY1125068T1 (el) | Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| CY1119149T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| CY1120267T1 (el) | Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας | |
| CY1119751T1 (el) | Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3 | |
| CY1118928T1 (el) | Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους | |
| CY1117476T1 (el) | Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων | |
| CY1115316T1 (el) | Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| CY1119376T1 (el) | Αντισωματα ειδικα για τη μορφη πρωτοϊνιδιου της βητα-αμυλοειδους πρωτεϊνης | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| DK1981981T3 (da) | Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter | |
| CY1121455T1 (el) | Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου | |
| CY1115798T1 (el) | Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2 | |
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CY1118918T1 (el) | Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης | |
| PE20230091A1 (es) | Conjugados terapeuticos |